اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,920
تعداد مقالات32,927
تعداد مشاهده مقاله43,414,650
تعداد دریافت فایل اصل مقاله19,893,859
Nesterova, N., Patrakhanov, E., Pokrovskii, V., Pirozhkov, I., Pokrovskaya, T., Levit, N., Ivanova, M., Kizi, S., Nesterov, A., Shutov, V., Hoshchenko, Y.. (1400). Investigation of Taurine Derivative Magnesium-Bis-(2-Aminoethanesulfonic)-Butadioateon Alleviation of Neurological Defects in Simulated Hemorrhagic Stroke in Rats. سامانه مدیریت نشریات علمی, 76(4), 985-994. doi: 10.22092/ari.2021.355884.1732
N. I Nesterova; E. A Patrakhanov; V. V Pokrovskii; I. V Pirozhkov; T. G Pokrovskaya; N. B Levit; M. I Ivanova; S. N. M Kizi; A. V Nesterov; V. I Shutov; Y. A Hoshchenko. "Investigation of Taurine Derivative Magnesium-Bis-(2-Aminoethanesulfonic)-Butadioateon Alleviation of Neurological Defects in Simulated Hemorrhagic Stroke in Rats". سامانه مدیریت نشریات علمی, 76, 4, 1400, 985-994. doi: 10.22092/ari.2021.355884.1732
Nesterova, N., Patrakhanov, E., Pokrovskii, V., Pirozhkov, I., Pokrovskaya, T., Levit, N., Ivanova, M., Kizi, S., Nesterov, A., Shutov, V., Hoshchenko, Y.. (1400). 'Investigation of Taurine Derivative Magnesium-Bis-(2-Aminoethanesulfonic)-Butadioateon Alleviation of Neurological Defects in Simulated Hemorrhagic Stroke in Rats', سامانه مدیریت نشریات علمی, 76(4), pp. 985-994. doi: 10.22092/ari.2021.355884.1732
Nesterova, N., Patrakhanov, E., Pokrovskii, V., Pirozhkov, I., Pokrovskaya, T., Levit, N., Ivanova, M., Kizi, S., Nesterov, A., Shutov, V., Hoshchenko, Y.. Investigation of Taurine Derivative Magnesium-Bis-(2-Aminoethanesulfonic)-Butadioateon Alleviation of Neurological Defects in Simulated Hemorrhagic Stroke in Rats. سامانه مدیریت نشریات علمی, 1400; 76(4): 985-994. doi: 10.22092/ari.2021.355884.1732

Investigation of Taurine Derivative Magnesium-Bis-(2-Aminoethanesulfonic)-Butadioateon Alleviation of Neurological Defects in Simulated Hemorrhagic Stroke in Rats

Archives of Razi Institute
مقاله 28، دوره 76، شماره 4، آذر و دی 2021، صفحه 985-994    اصل مقاله (812.59 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.355884.1732
نویسندگان
N. I Nesterova* 1؛ E. A Patrakhanov2؛ V. V Pokrovskii2؛ I. V Pirozhkov1؛ T. G Pokrovskaya2؛ N. B Levit1؛ M. I Ivanova2؛ S. N. M Kizi2؛ A. V Nesterov1؛ V. I Shutov3؛ Y. A Hoshchenko2
1Regional State Funded Healthcare Facility “Belgorod Forensic Medical Bureau”, 159, Volchanskaya St., Belgorod, 308017, Russia
2Belgorod State National Research University, 85, Pobeda St., Belgorod, 308015, Russia
3Belgorod Regional Hospital of St. Joasaph, 8/9, Nekrasova St., Belgorod, 308036, Russia
چکیده
Stroke or ischemia is caused by a blockage in a specific blood vessel that partially or completely reduces the blood flow to the brain. Nutritional factors such as antioxidants and healthy eating patterns are important variables in preventing stroke. Molecular composition properties such as molecular binding and screening can be used to evaluate the specific activity and morphological changes. The present study aimed to evaluate the effectiveness of pharmacological correction of the consequences of a hemorrhagic stroke in rats with a new derivative of taurine magnesium-bis-(2-aminoethanesulfonic)-butadioate. The animals (n=170) were divided into four groups as follows: 1) control group (n=20), 2) group 2 suffered a hemorrhagic stroke without pharmacological correction (n=50), 3) group 3 (n=50) underwent simulation of hemorrhagic stroke received Taurine at the dose of 50 mg/kg, 4) Group 4 underwent simulation of hemorrhagic stroke with correction of hemorrhagic stroke with magnesium-bis-(2-aminoethanesulfonic)-butadioate at the dose of 150 mg/kg (LKHT 3-17) (n=50). Hemorrhagic stroke was induced by transfusing autologous blood into the parietal lobe of the right hemisphere of the brain. Lethality, neurological status, locomotor, and exploratory behavior, as well as the morphological pattern of the brain damage, were assessed on the 1st, 3rd, and 7th days after the pathology simulation. Neurological deficit was determined in animals by the McGrow stroke index scale. The locomotor and exploratory behavior was evaluated using the Acti-track software and hardware complex. Two criteria were considered when assessing morphological changes in the brain: the average thickness of the cerebral cortex (in micrometers) and the number of neurons without degenerative changes. LKHT 3-17 (150 mg/kg) and taurine (50 mg/kg) reduced lethality by 1.7 and 1.36 times, respectively, on the 3rd day after stroke compared to that of the control (p<0.05). In parallel, a neurological deficit was effectively corrected LKHT 3-17 and taurine to 5.3±0.8 and 6.5±0.9, respectively, on the 1st day in contrast to the control of 8.1±0.7 points. The locomotor and exploratory behavior was significantly different on the 7th day and was accompanied by a significant increase in total activity under the influence of LKHT 3-17 to 491 conventional units (CU) compared to the control of 110 conventional units. On the 1st day, the thickness of the cortex was 1943.7±44.08 µm, and 1491.0±38.61 µm in the control and LKHT 3-17 groups, respectively. The number of neurons without neurodegenerative changes prevailed in LKHT 3-17 group (18.7±4.32), and the lowest number was observed in the group without pharmacological correction of the pathology (14.3±3.78). The taurine derivative magnesium-bis-(2-aminoethanesulfonic)-butadioate, which is a combination of the amino acid,  magnesium ion, and succinic acid, decreases the neurological deficits, lethality, and enhances the locomotor and exploratory behavior in experimental hemorrhagic stroke in rats. The effect of the studied medication on the dynamics of molecular pathophysiological mechanisms occurring in the cell requires additional research.


کلیدواژه‌ها
Hemorrhagic stroke؛ Neuroprotection؛ Taurine
سایر فایل های مرتبط با مقاله
مراجع
  1. Suzuki J, Ohara H. Clinicopathological study of cerebral aneurysms: origin, rupture, repair, and growth. J Neurosurg. 1978;48(4):505-14.
  2. Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med. 1992;326(11):733-6.
  3. Muzyko EA, Perfilova VN, Suvorin KV, Tyurenkov IN. The effect of early and late pharmacological correction with GABA derivatives of psychoemotional state of offspring of rats with experimental preeclampsia. Res Results Pharmacol. 2020;6:67.
  4. Narzullo S. Molecular docking, ADMET study and in vivo pharmacological research of N-(3, 4-dimetoxyphenyl)-2- acetamide as a promising anticonvulsant. Res Results Pharmacol. 2020;6(2).
  5. Roik RO, Lebedev AA, Shabanov PD. The value of extended amygdala structures in emotive effects of narcogenic with diverse chemical structure. Res Results Pharmacol. 2019;5(3):11-19.
  6. Semeleva EV, Blinova EV, Zaborovsky AV, Gromova IA, Shukurov AS, Blinov DS, et al. Metal-containing taurine compounds protect rat’s brain in reperfusion-induced injury. Res Results Pharmacol. 2020;6:43.
  7. Spasov AA, Kucheryavenko AF, Gaidukova KA, Kosolapov VA, Zhukovskaya ON. Antiplatelet activity of new derivatives of benzimidazole containing sterically hindered phenolic group in their structure. Res Results Pharmacol. 2020;6:1.
  8. Bezverkhniaia EA, Povet’eva TN, Kadyrova TV, Suslov NI, Nesterova YV, Ol’ga G, et al. Screening study for anticonvulsive activity of lipophilic fractions from empetrum nigrum L. Res Results Pharmacol. 2020;6:67.
  9. Maltsev DV, Spasov AA, Miroshnikov MV, Skripka MO, Divaeva LN. Influence of Diazepino [1, 2-a] benzimidazole derivative (DAB-19) on behavioral aspects of animals. Res Results Pharmacol. 2020;6:9.
  10. Jin R, Xiao AY, Liu S, Wang M, Li G. Taurine reduces tPA (tissue-type plasminogen activator)-induced hemorrhage and microvascular thrombosis after embolic stroke in rat. Stroke. 2018;49(7):1708-18.
  11. Schaffer S, Kim HW. Effects and mechanisms of taurine as a therapeutic agent. Biomol Ther. 2018;26(3):225.
  12. Wójcik OP, Koenig KL, Zeleniuch-Jacquotte A, Costa M, Chen Y. The potential protective effects of taurine on coronary heart disease. Atherosclerosis. 2010;208(1):19-25.
  13. Huxtable R. Physiological actions of taurine. Physiol Rev. 1992;72(1):101-63.
  14. Mizushima S, Nara Y, Sawamura M, Yamori Y. Effects of oral taurine supplementation on lipids and sympathetic nerve tone. Taurine 2: Springer; 1996. p. 615-22.
  15. Zhang M, Bi L, Fang J, Su X, Da G, Kuwamori T, et al. Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids. 2004;26(3):267-71.
  16. Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75(3):525-32.
  17. LIU L, LIU L, DING Y, HUANG Z, HE B, SUN S, et al. Ethnic and environmental differences in various markers of dietary intake and blood pressure among Chinese Han and three other minority peoples of China: results from the WHO Cardiovascular Diseases and Alimentary Comparison (CARDIAC) Study. Hypertens Res. 2001;24(3):315-22.
  18. Mizushima S, Moriguchi EH, Ishikawa P, Hekman P, Nara Y, Mimura G, et al. Fish intake and cardiovascular risk among middle-aged Japanese in Japan and Brazil. Eur J Cardiovasc Prev Rehabil 1997;4(3):191-9.
  19. Sagara M, Murakami S, Mizushima S, Liu L, Mori M, Ikeda K, et al. Taurine in 24-h urine samples is inversely related to cardiovascular risks of middle aged subjects in 50 populations of the world. Taurine 9: Springer; 2015. p. 623-36.
  20. Yamori Y, Liu L, Mori M, Sagara M, Murakami S, Nara Y, et al. Taurine as the nutritional factor for the longevity of the Japanese revealed by a world-wide epidemiological survey. Taurine 7: Springer; 2009. p. 13-25.
  21. Majid A. Neuroprotection in stroke: past, present, and future. Int Sch Res Notices 2014;2014.
  22. Menzie J, Prentice H, Wu J-Y. Neuroprotective mechanisms of taurine against ischemic stroke. Brain Sci. 2013;3(2):877-907.
  23. Pan C, Giraldo GS, Prentice H, Wu J-Y. Taurine protection of PC12 cells against endoplasmic reticulum stress induced by oxidative stress. J Biomed Sci. 2010;17(1):1-7.
  24. AV. N. A method for modeling hemorrhagic stroke in rats. Patent for invention. 2020.
  1. McGraw CP, Pashayan A, Wendel O. Cerebral infarction in the Mongolian gerbil exacerbated by phenoxybenzamine treatment. Stroke. 1976;7(5):485-8.
  2. Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs. 2007;12(3):389-406.
  3. Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 2011;42(6):1781-6.
  4. Chen S, Zeng L, Hu Z. Progressing haemorrhagic stroke: categories, causes, mechanisms and managements. J Neurol. 2014;261(11):2061-78.
  5. El Idrissi A, Trenkner E. Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism. J Neurosci 1999;19(21):9459-68.
  6. Schaffer S, Azuma J, Takahashi K, Mozaffari M. Why is taurine cytoprotective? Taurine 5. 2003:307-21.
  7. Fawcett W, Haxby E, Male D. Magnesium: physiology and pharmacology. Br J Anaesth. 1999;83(2):302-20.
32.          Rowland M, Hadjipavlou G, Kelly M, Westbrook J, Pattinson K. Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br J Anaesth. 2012;109(3):315-29.

آمار
تعداد مشاهده مقاله: 1,176
تعداد دریافت فایل اصل مقاله: 502


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب